ijerph-logo

Journal Browser

Journal Browser

Novel Insights into Atrial Fibrillation

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Health Behavior, Chronic Disease and Health Promotion".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 4036

Special Issue Editor


E-Mail Website
Guest Editor
Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria
Interests: atrial fibrillation; cardiopulmonary resuscitation; epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Atrial fibrillation (AF) is a well-known disease that affects a large share of patients treated by the medical community and is, therefore, a public health issue. Despite the existence of clear guidelines, it is not one of your "everyday" problems with a straightforward, one-size-fits-all treatment plan, but rather a complex disease necessitating different approaches depending on which side of it you are looking at: a nuisance to daily life in patients with paroxysmal or persistent AF leading to recurring cardioversions, ablations, or chronic medical therapies; a major stroke risk and cause; a complicator of post-operative hospital stays; a cause for emergency department visits; up to a negative impactor on critical care and intensive care—AF shows its facets in many different ways.

"Novel insights" concerning AF in every possible aspect impacting patients are needed for further evolving modern and specific diagnostic, therapeutic, and preventive aspects of this disease. Papers addressing these topics are invited for this Special Issue of IJERPH, especially those focusing on either practical approaches or raising new thoughts leading to potential future research.

Dr. Sebastian Schnaubelt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atrial fibrillation
  • arrhythmia
  • dysrhythmia
  • electrophysiology
  • post-operative atrial fibrillation
  • critical care

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

5 pages, 282 KiB  
Editorial
From Bench to Bedside—Implementing the New ABC Approach for Atrial Fibrillation in an Emergency Department Setting
by Sophie Gupta, Martin Lutnik, Jan Niederdöckl and Sebastian Schnaubelt
Int. J. Environ. Res. Public Health 2022, 19(8), 4797; https://doi.org/10.3390/ijerph19084797 - 15 Apr 2022
Cited by 2 | Viewed by 1583
Abstract
Atrial fibrillation (AF) is a globally evolving medical challenge with, currently, 4% prevalence in the European Union’s population [...] Full article
(This article belongs to the Special Issue Novel Insights into Atrial Fibrillation)

Research

Jump to: Editorial

11 pages, 2156 KiB  
Article
Cardioversion of Post-Ablation Atrial Tachyarrhythmia with Ibutilide and Amiodarone: A Registry-Based Cohort Study
by Filippo Cacioppo, Michael Schwameis, Nikola Schuetz, Julia Oppenauer, Sebastian Schnaubelt, Alexander Simon, Martin Lutnik, Sophie Gupta, Dominik Roth, Harald Herkner, Alexander Oskar Spiel, Anton Norbert Laggner, Hans Domanovits and Jan Niederdoeckl
Int. J. Environ. Res. Public Health 2022, 19(11), 6606; https://doi.org/10.3390/ijerph19116606 - 28 May 2022
Cited by 1 | Viewed by 1950
Abstract
Patients with recurrence of atrial tachyarrhythmia after catheter ablation for atrial fibrillation or atrial flutter constitute a rapidly growing cohort, but study-driven treatment recommendations are lacking. The present study aimed to compare the cardioversion success of ibutilide and amiodarone in patients with post-ablation [...] Read more.
Patients with recurrence of atrial tachyarrhythmia after catheter ablation for atrial fibrillation or atrial flutter constitute a rapidly growing cohort, but study-driven treatment recommendations are lacking. The present study aimed to compare the cardioversion success of ibutilide and amiodarone in patients with post-ablation atrial tachyarrhythmia. We included all episodes of post-ablation atrial tachyarrhythmia in patients treated with either intravenous ibutilide or amiodarone at an academic emergency department from 2010 to 2018. The primary endpoint was the conversion to sinus rhythm. The conversion rates were stratified by arrhythmia type, and multivariable cluster-adjusted logistic regression was used to estimate the effect of ibutilide and amiodarone on cardioversion success, given as the odds ratio (OR) with 95% confidence intervals (95% CI). In total, 109 episodes of 72 patients were analyzed. The conversion rates were 37/49 (76%) for ibutilide and 16/60 (27%) for amiodarone. Compared to amiodarone, ibutilide was associated with higher odds of conversion (multivariable cluster-adjusted OR 5.6, 95% CI 1.3–24.3). The cardioversion success of ibutilide was the highest in atrial flutter (crude OR 19.5, 95% CI 3.4–112.5) and focal atrial tachycardia (crude OR 8.3, 95% CI 1.5–47.2), but it was less pronounced in atrial fibrillation (crude OR 4.5, 95% CI 1.2–17.2). Randomized trials are warranted to confirm our findings. Full article
(This article belongs to the Special Issue Novel Insights into Atrial Fibrillation)
Show Figures

Figure 1

Back to TopTop